国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析

doi:10.3969/j.issn.1000-6621.2020.02.003

中国防痨杂志 ›› 2020, Vol. 42 ›› Issue (2): 91-94.doi: 10.3969/j.issn.1000-6621.2020.02.003

所属专题：标准、共识、指南

国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析

范琳(),刘一典,肖和平()

200433 同济大学附属上海市肺科医院结核病临床研究中心上海市结核病(肺)重点实验室

收稿日期:2019-12-21 出版日期:2020-02-10 发布日期:2020-02-19
通信作者: 范琳,肖和平 E-mail:fanlinsj@163.com;xiaoheping_sars@163.com

Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis (2019) and associated consensus

FAN Lin(),LIU Yi-dian,XIAO He-ping()

Shanghai Pulmonary Hospital, Clinic and Research Center of Tuberculosis, Shanghai Key Lab of Tuberculosis, Tongji University School of Medicine, Shanghai 200433,China

Received:2019-12-21 Online:2020-02-10 Published:2020-02-19
Contact: Lin FAN,He-ping XIAO E-mail:fanlinsj@163.com;xiaoheping_sars@163.com

摘要/Abstract

摘要：

作者针对国内《耐药结核病化学治疗指南(2019年)》(简称“《指南(2019)》”)与《中国耐多药结核病和利福平耐药结核病治疗专家共识(2019年版)》的异同进行具体分析,并与WHO相关指南进行比对,从药物的分组、抗结核治疗的实施路径、《指南(2019)》的特色与国内耐药结核病治疗研究的发展方向等方面进行阐述,为临床一线医师对指南的理解提供思路。

关键词: 结核,抗多种药物性, 利福平, 总结性报告(主题), 指南, 评论

Abstract:

Authors made analysis on the similarities and differences of Chinese Guidelines on chemotherapy of drug-resistant tuberculosis (2019) (abbreviated as “Guidelines 2019”) and Chinese consensus on multidrug-resistant tuberculosis and rifampin resistant tuberculosis treatment (2019 edition) and compared with WHO guidelines, provided the ideas from the elaboration on drug groups divided, implement approach of anti-TB treatment,the characteristics of Guidelines 2019 and future development direction of national drug-resistant treatment for clinical physicians.

Key words: Tuberculosis,multidrug-resistant, Rifampin, Consensus development conferences as topic, Guidebooks, Comment

范琳,刘一典,肖和平. 国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析[J]. 中国防痨杂志, 2020, 42(2): 91-94. doi: 10.3969/j.issn.1000-6621.2020.02.003

FAN Lin,LIU Yi-dian,XIAO He-ping. Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis (2019) and associated consensus[J]. Chinese Journal of Antituberculosis, 2020, 42(2): 91-94. doi: 10.3969/j.issn.1000-6621.2020.02.003

参考文献 16

[1]	中华医学会结核病学分会. 中国耐多药结核病和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019,42(10):733-749.
[2]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073.
[3]	中国防痨协会. 耐药结核病化学治疗指南(2019年).北京:人民卫生出版社, 2019.
[4]	World Health Organization . WHO consolidated guidelines on drug-resistant tuberculosis. Geneva: World Health Organization, 2019.
[5]	Sharma AK, Gupta N, Kala DK , et al. A study on pattern of resistance to second line anti tubercular drugs among multi drug resistant tuberculosis patients. Indian J Tuberc, 2018,65(3):233-236.
[6]	Salvato RS, Costa ERD, Reis AJ , et al. First insights into circulating XDR and pre-XDR Mycobacterium tuberculosis in Southern Brazil. Infect Genet Evol, 2019,78:104127.
[7]	World Health Organization . Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2014.
[8]	World Health Organization . WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
[9]	Dawson R, Diacon AH, Everitt D , et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet, 2015,385(9979):1738-1747.
[10]	中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
[11]	申晓娜, 赵雁林, 肖和平 , 等. 对氨基水杨酸异烟肼及异烟肼体外抗结核分枝杆菌活性分析. 中华结核和呼吸杂志, 2014,37(2):132-134.
[12]	吴哲渊, 张青, 张祖荣 , 等. 上海市耐多药肺结核防治管理模式效果评价. 中国防痨杂志, 2015,37(11):1118-1125.
[13]	闫丽萍, 吴哲渊, 张祖荣 , 等. 初治耐多药肺结核患者采用初治标准方案治疗的前瞻性临床研究. 中国防痨杂志, 2017,39(1):33-38.
[14]	Lee M, Mok J, Kim DK , et al. Delamanid, linezolid, levoflo-xacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treat-ment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials, 2019,20(1):57.
[15]	Sarin R, Vohra V, Singla N , et al. Early efficacy and safety of Bedaquiline and Delamanid given together in a “Salvage Regimen” for treatment of drug-resistant tuberculosis. Indian J Tuberc, 2019,66(1):184-188.
[16]	Olayanju O, Esmail A, Limberis J , et al. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis. Eur Respir J , 2019,pii:1901181.

国内《耐药结核病化学治疗指南(2019年)》与相关共识的特色及要点分析

Characteristics and points analysis of national Guidelines on chemotherapy of drug-resistant tuberculosis (2019) and associated consensus

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 16

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	靳鸿建. 我国县级结核病防治服务体系建设及防治工作亟需加强——一位老防痨工作者的意见和建议[J]. 中国防痨杂志, 2020, 42(9): 896-902.
[2]	张灿有, 夏辉, 成君. Ⅱ级生物安全柜在结核病实验室中的检测及报告要求[J]. 中国防痨杂志, 2020, 42(9): 903-909.
[3]	中国防痨协会中国防痨协会学校与儿童结核病防治专业分会《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识[J]. 中国防痨杂志, 2020, 42(8): 761-768.
[4]	首都医科大学附属北京胸科医院中国防痨协会非结核分枝杆菌分会《中国防痨杂志》编辑委员会. 非结核分枝杆菌病治疗药品超说明书用法专家共识[J]. 中国防痨杂志, 2020, 42(8): 769-787.
[5]	李涛, 杜昕, 陈伟, 黄飞, 赵雁林, 张慧. 中国结核病管理信息监测与监控的回顾与展望[J]. 中国防痨杂志, 2020, 42(7): 657-661.
[6]	曾谊, 高卫卫, 宫素岗, 侯代伦. 二例结核感染所致纵隔纤维化患者的临床诊治过程分析[J]. 中国防痨杂志, 2020, 42(7): 747-751.
[7]	首都医科大学附属北京胸科医院中国防痨协会临床试验专业分会《中国防痨杂志》编辑委员会. 环丝氨酸治疗结核病的临床用药指南[J]. 中国防痨杂志, 2020, 42(6): 533-540.
[8]	沈鑫, 沙巍, 刘剑君. 新型冠状病毒肺炎疫情对结核病防控的影响及对策[J]. 中国防痨杂志, 2020, 42(6): 544-548.
[9]	宋其生, 路希维. 正电子发射计算机体层摄影-CT在肺结核临床研究中的应用进展与展望[J]. 中国防痨杂志, 2020, 42(6): 621-625.
[10]	首都医科大学附属北京胸科医院, 中国防痨协会临床试验专业分会, 《中国防痨杂志》编辑委员会. 氯法齐明治疗结核病的临床应用指南[J]. 中国防痨杂志, 2020, 42(5): 409-417.
[11]	成君, 刘剑君. 我国学校结核病疫情监测和预警的现状与进展[J]. 中国防痨杂志, 2020, 42(5): 436-441.
[12]	张培泽, 郑俊峰, 曹炜鹏, 王玉香, 陈涛, 付亮, 邓国防. 服用利福平后两个时间点监测血药浓度的研究[J]. 中国防痨杂志, 2020, 42(5): 493-497.
[13]	卢鹏,成君,路希维,刘二勇,周林,陆伟. 科学开展预防性治疗加速遏制结核病进程[J]. 中国防痨杂志, 2020, 42(4): 316-321.
[14]	周银发,张山鹰,戴志松,陈代权,李卫林,赵永,林淑芳. 福建省耐药肺结核高危人群利福平耐药情况及其影响因素分析[J]. 中国防痨杂志, 2020, 42(4): 339-344.
[15]	范欣欣,吴迪,林友飞,陈晓红. 阿达木单抗治疗强直性脊柱炎致播散性结核病一例并文献复习[J]. 中国防痨杂志, 2020, 42(4): 391-397.